Shandong Luye Pharmaceutical Co., Ltd.

Tripeptide compounds containing sulfhydryl (SH) groups have important physiological activities in the human body, such as activating the redox system, activating SH enzymes, and detoxifying. They participate in the tricarboxylic acid cycle and sugar metabolism in the body, promote the production of high energy in the body, and act as a coenzyme. They are the cofactor of glyceraldehyde phosphate dehydrogenase, and the coenzyme of glyoxalase and triose phosphate dehydrogenase. They can activate SH enzymes in the body, promote the metabolism of carbohydrates, fats, and proteins, and regulate the metabolic process of cell membranes. They participate in the combination of various exogenous and endogenous toxic substances to produce attenuated substances.

It helps the body to increase the plasma concentration of ACTH and cortisone, promotes the secretion of PGF2alpha by the blood vessel wall, removes free radicals in the body, fights inflammation and exudation, increases venous tension, speeds up venous blood flow, promotes lymphatic return, improves blood circulation and microcirculation, and protects the blood vessel wall.

It helps the body to increase the plasma concentration of ACTH and cortisone, promotes the secretion of PGF2alpha by the blood vessel wall, removes free radicals in the body, fights inflammation and exudation, increases venous tension, speeds up venous blood flow, promotes lymphatic return, improves blood circulation and microcirculation, and protects the blood vessel wall.

It prompts the body to increase the plasma concentration of ACTH and cortisone, promotes the blood vessel wall to increase the secretion of PGF2alpha, scavenges free radicals in the body, has anti-inflammatory and anti-exudation effects, increases venous tension, accelerates venous blood flow, promotes lymphatic return, improves blood circulation and microcirculation, and protects the blood vessel wall.

It prompts the body to increase the plasma concentration of ACTH and cortisone, promotes the blood vessel wall to increase the secretion of PGF2alpha, scavenges free radicals in the body, has anti-inflammatory and anti-exudation effects, increases venous tension, accelerates venous blood flow, promotes lymphatic return, improves blood circulation and microcirculation, and protects the blood vessel wall.

It can help the body increase the plasma concentration of ACTH and cortisone, promote the secretion of PGF2alpha by the blood vessel wall, remove free radicals in the body, resist inflammation and exudation, increase venous tension, speed up venous blood flow, promote lymphatic return, improve blood circulation and microcirculation, and protect the blood vessel wall.

It can help the body increase the plasma concentration of ACTH and cortisone, promote the secretion of PGF2alpha by the blood vessel wall, remove free radicals in the body, resist inflammation and exudation, increase venous tension, speed up venous blood flow, promote lymphatic return, improve blood circulation and microcirculation, and protect the blood vessel wall.

This drug is a hypoglycemic sulfonylurea-oral diabetes treatment drug. Gliclazide lowers blood sugar levels by stimulating pancreatic β cells to secrete insulin. For type 2 diabetes, gliclazide can restore the first-phase insulin secretion peak in response to glucose and increase the second-phase insulin secretion. It can be seen that the insulin secretion response induced or stimulated by glucose after a meal is significantly increased.